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ABSTRACT
A cell culture assembly and a method for culturing cells that
provide mechanical stimulation to cells. The cell culture
assembly can include a flow chamber positioned in a fluid
path and a support comprising cells positioned within the flow
chamber to expose the cells to the fluid path. The cell culture
assembly can further include a means for producing a steady
flow of fluid in the fluid path, and a means for producing an
oscillatory flow of fluid in the fluid path simultaneously with
producing the steady flow of fluid in the fluid path to mechani
cally stimulate the cells. The method can include transporting
fluid in the fluid path at a substantially steady flow rate, and
transporting fluid in the fluid path at a substantially oscilla
tory flow rate simultaneously with transporting fluid in the
fluid path at a substantially steady flow rate.
8 Claims, 3 Drawing Sheets
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CELL CULTURE METHOD AND APPARATUS
LOR MECHANICALLY STIMULATING
CELLS
BACKGROUND
The present invention generally relates to a cell culture
method and apparatus for mechanically stimulating cells,
including bone cells, ligament cells, tendon cells, cartilage
cells, muscle cells, blood vessel cells, and nerve cells. Cell
and tissue graft therapy have been used to treat defects for
many clinical disorders, including trauma and cancer.
Autografts and allografts have also been used as grafting
treatments for tissue repair. However, there is a limited supply
of tissue that is available for autograft transplantation.
Autografting requires an additional suigery which can lead to
donor site morbidity and pain. Allografts have the risks of
disease transmission and transplant failure due to immune
response, fracture, or non-union. Due to the limitations of
grafting, alternative therapies such as tissue engineering can
be used, including three-dimensional tissue engineering.
SUMMARY
Mechanical loading can enhance cell growth and engineer
ing tissue development. For example, mechanical loading can
increase bone cell proliferation and matrix production in
vitro. Mechanical loading can also increase bone formation in
vivo, and can help regulate bone tissue mechanical properties.
Cell adaptation to mechanical loading is believed to be medi
ated by cell mechanotransduction, which is the process of
cells detecting mechanical stimuli and converting them into
biochemical signals. These signals act on effector cells (e.g.,
osteoclasts and osteoblasts in bone) to carry out the tissue
level adaptations. Cell shear stress induced by fluid flow in the
porous spaces of bone can act as a mechanical stimulus in
activating mechanotransduction signaling and mediating
adaptation. In vivo levels of cell shear stress are estimated to
be in the range of 0.8-3 Pa. Consequently, fluid flow-induced
shear stress can be used as a mechanical stimulus to study
mechanotransduction in vitro. Cell mechanotransduction can
be analyzed by monitoring media that has flown through a
flow chamber housing cells. Additionally, cells can behave
differently when cultured in a three-dimensional environment
than in a two-dimensional monolayer.
In some embodiments of the present invention, a cell cul
ture assembly is provided. The cell culture assembly can
include a flow chamber positioned in a fluid path and a sup
port comprising cells positioned within the flow chamber to
expose the cells to the fluid path. The cell culture assembly
can further include a means for producing a steady flow of
fluid in the fluid path to transport nutrients to the cells and to
carry conditioned media away from the cells, and a means for
producing an oscillatory flow of fluid in the fluid path simul
taneously with producing the steady flow of fluid in the fluid
path to mechanically stimulate the cells.
Some embodiments of the present invention provide a cell
culture assembly. The cell culture assembly can include a
fluid path through which fluid flows in the cell culture assem
bly. The cell culture assembly can include a flow chamber
positioned in the fluid path. The cell culture assembly can
further include a support positioned within the flow chamber
and the support may include cells. The cell culture assembly
can also include a first pump and a second pump positioned in
fluid communication with the flow chamber. The first pump
can be adapted to produce a steady flow of fluid in the fluid
path. The second pump can be adapted to produce an oscil
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2

latory flow of fluid in the fluid path simultaneously with
production of the steady flow of fluid.
In some embodiments of the present invention, a method
for culturing cells is provided. The method can include pro
viding a flow chamber positioned in a fluid path. The method
can further include providing a support positioned within the
flow chamber, the support comprising cells. The method can
also include transporting fluid in the fluid path at a substan
tially steady flow rate to transport fluid over the cells. The
method can further include transporting fluid in the fluid path
at a substantially oscillatory flow rate simultaneously with
transporting fluid in the fluid path at a substantially steady
flow rate.
Other features and aspects of the invention will become
apparent by consideration of the detailed description, accom
panying drawings and claims.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is a schematic diagram of a cell culture assembly
according to one embodiment of the present invention, the
cell culture assembly including a plurality of flow chambers.
FIG. 2 is a cross-sectional view of one of the flow chambers
of FIG. 1.
FIG. 3 is a bar graph illustrating experimental results for
culturing bone cells in a cell culture assembly according to
one embodiment of the present invention, as described in
Examples 1 and 2.
DETAILED DESCRIPTION
Before any embodiments of the invention are explained in
detail, it is to be understood that the invention is not limited in
its application to the details of construction and the arrange
ment of components set forth in the following description or
illustrated in the following drawings. The invention is capable
of other embodiments and of being practiced or of being
carried out in various ways. Also, it is to be understood that
the phraseology and terminology used herein is for the pur
pose of description and should not be regarded as limiting.
The use of “including,” “comprising,” or “having” and varia
tions thereof herein is meant to encompass the items listed
thereafter and equivalents thereof as well as additional items.
Unless specified or limited otherwise, the terms “mounted,”
“connected,” “supported,” and “coupled” and variations
thereof are used broadly and encompass both direct and indi
rect mountings, connections, supports, and couplings. Fur
ther, “connected” and “coupled” are not restricted to physical
or mechanical connections or couplings. Furthermore, terms
such as “front,” “rear,” “top,” “bottom,” and the like are only
used to describe elements as they relate to one another, but are
in no way meant to recite specific orientations of the appara
tus, to indicate or imply necessary or required orientations of
the apparatus, or to specify how the invention described
herein will be used, mounted, displayed, or positioned in use.
The present invention relates to cell culture assemblies that
employ a steady flow of fluid and an oscillatory flow of fluid
to mechanically stimulate cells. The focus of the description
below will be on a cell culture assembly for culturing bone
cells on tissue engineering scaffolds. However, it should be
noted that the present invention can be extended to the stimu
lation of other types of cells on various types of supports
without departing from the spirit and scope of the present
invention. That is, the present invention can be extended to the
stimulation of a variety of cells, including, without limitation,
bone cells, ligament cells, tendon cells, cartilage cells, muscle
cells (e.g., skeletal muscle cells, cardiac muscle cells and
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smooth muscle cells), blood vessel cells, and nerve cells.
Various aspects of the present invention have been described
in a paper by J. L. Vance, S. A. Galley, and S. W. Donahue,
entitled, “Mechanical stimulation of MC3T3 osteoblastic
cells in a bone tissue engineering bioreactor enhances PGE2
release,” which was presented at the 51 st Annual Meeting of
the Orthopaedic Research Society in Washington DC on Feb.
21-23, 2005, and which is incorporated herein by reference.
As used herein and in the appended claims, the terms
“upstream” and “downstream” refer to the direction of steady
fluid movement in a cell culture assembly. That is, the term
“upstream” is used to describe any location, element or pro
cess that occurs prior to the point or area being referred to
relative to the direction of steady (i.e., not oscillatory) fluid
movement in a cell culture assembly, whereas the term
“downstream” is used to describe any location, element or
process that occurs subsequent to the point or area of refer
ence with respect to steady fluid movement in the cell culture
assembly. Although oscillatory flow in the cell culture assem
bly may at least temporarily reverse the direction of fluid
movement, the terms “upstream” and “downstream” remain
defined relative to the steady flow. Furthermore, the terms
“upstream” and “downstream” are defined assuming a posi
tive steady flow in the cell culture assembly (i.e., not suction)
from a first pump and a second pump to one or more flow
chambers. The steady flow of fluid can include negative,
reverse steady flow, but such negatively directed flow will not
affect how “upstream” and “downstream” are defined herein.
As used herein and in the appended claims, the term “fluid
path” refers collectively to those areas in the cell culture
assembly through which fluid passes. A “fluid path” can refer
to an entire path followed by fluid through the cell culture
assembly or can refer to a portion of that path.
As used herein and in the appended claims, the term “flow
chamber” refers to a reservoir that is positioned in a fluid path
to expose at least a portion of the interior of the flow chamber
to the fluid flowing in the fluid path, the flow chamber being
in fluid communication with the fluid path. In some embodi
ments, the flow chamber serves as the final destination of the
fluid path, and the fluid need not necessarily flow through the
flow chamber.
As used herein and in the appended claims, the term “sup
port” refers to any two-dimensional or three-dimensional
structure to which the cells may be bound, or within which the
cells can be contained. The “support” can include porous or
nonporous material. The “support” can be biologically modi
fied to enhance binding of the cells of interest, including
having ligands adsorbed to the support to promote the binding
of cell receptors of interest.
As used herein and in the appended claims, the term “cells”
refers to a variety of cells including, but not limited to, at least
one of bone cells (e.g., osteoblasts, osteoclasts, etc.), ligament
cells (e.g., fibroblasts, etc.), tendon cells (e.g., fibroblasts,
etc.), cartilage cells (e.g., chondrocytes, etc.), muscle cells
(e.g., skeletal muscle cells, cardiac muscle cells, smooth
muscle cells, etc.), blood vessel cells (e.g., smooth muscle
cells, endothelial cells, etc.), and nerve cells (e.g., neurons,
astrocytes, oligodendrocytes, etc.).
As used herein and in the appended claims, the term
“pump” refers to a device that moves a fluid (i.e., a liquid or
gas) by pressure and/or suction.
As used herein and in the appended claims, the term
“steady flow” refers to a flow having a substantially steady
magnitude that is substantially either all positive or all nega
tive.
As used herein and in the appended claims, the term “oscil
latory flow” refers to a flow having an oscillatory magnitude.
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The oscillatory flow includes a symmetrically oscillatory
magnitude, an asymmetrically oscillating magnitude, and
combinations thereof. In some embodiments, the oscillatory
flow includes a positive portion and a negative portion. In
some embodiments, the oscillatory flow includes pulsatile
flow, wherein the flow is oscillatory in magnitude, but is either
all positive or all negative.
As used herein and in the appended claims, the term “bio
molecule” refers to a molecule, or a derivative thereof, that
occurs in or is formed by a living cell. A biomolecule can
include, without limitation, at least one of an amino acid, a
nucleic acid, a polypeptide, a polynucleotide, a lipid, a phos
pholipid, a saccharide, a polysaccharide, and combinations
thereof. Furthermore, a biomolecule can include, without
limitation, at least one of mRNA, total RNA, genomic DNA,
plasmid DNA, plant DNA, a protein, a hormone, a growth
factor, an antibody, an antigen, and combinations thereof.
As used herein and in the appended claims, the term “con
ditioned media” refers to experimental culture media that has
flown through the cell culture assembly, and which can be
used for biochemical analysis. For example, the conditioned
media can be collected and then analyzed for the presence of
a biomolecule of interest. In some embodiments, the condi
tioned media can include cellular waste products.
As used herein and in the appended claims, the term “injec
tion port” refers to a point in the fluid path wherein a biomol
ecule may be delivered into the fluid path. An “injection port”
may be located at any point along the fluid path to allow a
biomolecule to be delivered at any point along the fluid path.
FIGS. 1 and 2 illustrate a cell culture assembly 100 for
applying a steady flow of fluid and an oscillatory flow of fluid
to cells 102 according to one embodiment of the invention. As
shown in FIG. 1, the cell culture assembly 100 includes a fluid
path 105 through which fluid flows in the cell culture assem
bly 100, a first pump 110 forproducing a steady flow of fluid,
and a second pump 115 for producing an oscillatory flow of
fluid. The cell culture assembly 100, as shown in FIG. 1,
further includes a first connector 120 (e.g., a three-way valve)
positioned in the fluid path 105 to combine the steady flow
and the oscillatory flow of fluid; a detector 125 for detecting
at least one of the steady flow and the oscillatory flow of fluid;
a controller 130 for controlling the flow rate of the steady flow
of fluid, and the flow rate and frequency of the oscillatory flow
of fluid; a media source 132 (e.g., a syringe) which allows for
the transfer of fresh media into the fluid path 105 sub stantially
without contamination via a second connector 122 (e.g., a
three-way valve); and an injection port 135 which can be used
in some embodiments to introduce a biomolecule of interest
to the fluid path 105. As shown by FIGS. 1 and 2, the cell
culture assembly 100 also includes one or more flow cham
bers 145, one or more supports 150 comprising cells 102, and
one or more collection reservoirs 155. The fluid flowing
through the fluid path 105 can include, but is not limited to,
cell culture media. In some embodiments, transfer of fresh
media into the fluid path 105 via the media source 132 is not
necessary, and such embodiments do not include the media
source 132.
The first pump 110 is adapted to produce a steady flow of
fluid in the fluid path 105 to transport nutrients to the cells 102
and, in some embodiments, to carry conditioned media 159
away from the cells 102. The second pump 115 is adapted to
produce an oscillatory flow of fluid in the fluid path 105
simultaneously with the production of the steady flow of fluid
to mechanically stimulate the cells 102. The oscillatory flow
of fluid generated by the second pump 115 is interposed with
the steady flow of fluid generated from the first pump 110 via
the first connector 120. The first connector 120 is positioned
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downstream from the first pump 110 and the second pump
115 and upstream from the flow chamber 145. The first con
nector 120 can be positioned at any position in the fluid path
105 to interpose the steady flow and oscillatory flow of fluid
produced by the first pump 110 and the second pump 115,
respectively. In some embodiments, the first pump 110 and
the second pump 115 are each directly fluidly coupled to each
flow chamber 145, or to a manifold that supplies fluid to each
flow chamber 145, and such embodiments do not include the
first connector 120.
Each flow chamber 145 is positioned downstream from and
is fluidly coupled to the first connector 120. Each flow cham
ber 145 includes a support 150. The flow chamber 145 and the
support 150 are positioned to expose at least a portion of the
flow chamber 145 and the support 150 to fluid flowing in the
fluid path 105. Each collection reservoir 155 is positioned
downstream from and is fluidly coupled to a flow chamber
145 to collect conditioned media 159 from the flow chamber
145.
The detector 125 is positioned downstream from one or
both of the first pump 110 and the second pump 115, and can
be fluidly coupled to the fluid path 105 at any point along the
fluid path 105. In some embodiments, the detector 125
includes a flow probe (e.g., In-line Series Flowprobes flow
probe, available from Transonic Systems Inc.®, Ithaca, N.Y.)
for measuring the flow rate and/or frequency of the fluid
flowing in the fluid path 105. The detector 125 can be used to
monitor one or more of the following from at least one of the
first pump 110 and the second pump 115: flow rate, pressure,
temperature, frequency, etc.
In some embodiments, the detector 125 is adapted to send
feedback to the controller 130, which can control at least one
of the first pump 110 and the second pump 115, based upon
the feedback from the detector 125. The media source 132 can
be manually activated to deliver fresh media to the fluid path
105, or the media source 132 can include a programmable
pump, or a pump that can be controlled by the controller 130,
similar to that ofthe first pump 110 and the second pump 115.
Similarly, the injection port 135 can include a manuallydriven device to introduce a biomolecule of interest to the
fluid path 105, or the injection port 135 can include an elec
tronically-driven or programmable pump that can be con
trolled by the controller 130.
The controller 130 can be connected to the first pump 110,
the second pump 115, the detector 125, and in some embodi
ments, the media source 132. In some embodiments, the
controller 130 of the cell culture assembly 100 is micropro
cessor-based and is adapted to manipulate and control the first
pump 110 to control the flow rate of the steady flow of fluid,
and/or the second pump 115 to control the flow rate and
frequency of the oscillatory flow of fluid. Additionally, in
some embodiments, the controller 130 can control the flow
rate at which fresh media is introduced to the fluid path 105
via the media source 132. In other embodiments, the control
ler 130 can include any programmable ornon-programmable
electronic system, and need not necessarily be microproces
sor-based. The controller 130 can include any combination of
hardware and/or software components, and can include more
than one controller device. In addition, the controller 130 can
include one or more independently-functioning or dependently-functioning units, such as a first controller that con
trols the first pump 110, a second controller that controls the
second pump 115, and a third controller that controls the
media source 132. By way of example only, the controller 130
can include any number of discrete logic elements coupled
together to perform the same function(s) as described above.
Still other types of electronic controllers capable of perform
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ing these function are possible, would be readily recognized
by those skilled in the art, and fall within the spirit and scope
of the present invention. In some embodiments, the first pump
110, the second pump 110, the media source 132, and/or a
driving device for delivering fluid via the injection port 135
can be controlled manually, and the controller 130 is not
required.
The injection port 135 of the illustrated embodiment is
positioned downstream in the fluid path 105 from the first
pump 110 and the second pump 115, and upstream from the
flow chamber 145. Elowever, the injection port 135 can be
positioned at any point in the fluid path 105 upstream of the
flow chambers 145 to introduce a biomolecule of interest to
the fluid path 105 to produce a desired effect in the cells 102.
For example, in some embodiments, the cells 102 include
bone cells, and a parathyroid hormone can be delivered (e.g.,
as a bolus injection) at the injection port 135 prior to (e.g.,
about 30 minutes before) activating the second pump 115 and
introducing the mechanically-stimulating oscillatory flow of
fluid to the cells 102. Parathyroid hormone has been found to
increase the responsiveness of bone cells to mechanical
stimulation. Other biomolecules of interest can be delivered
in a similar manner, depending on the cells 102 used, and the
desired effect. In some embodiments, a plurality of injection
ports 135 can be used to introduce a variety of biomolecules
to the fluid path 105. In other embodiments, introduction of a
biomolecule to the fluid path 105 is not necessary, and the cell
culture assembly 100 does not include an injection port 135.
The first pump 110 can include, but is not limited to, at least
one of a syringe pump, a peristaltic pump, and some other
type of linear or non-linear actuator. For example, in some
embodiments, such as the embodiment illustrated in FIG. 1,
the first pump 110 includes a programmable syringe pump
(e.g., a Remote Infuse/Withdraw PF1D 4400 Hpsi Program
mable Syringe Pump, available from Flarvard Apparatus,
Flollistion, Mass.) coupled to a first fluid source 152 (e.g., a
syringe) where the first pump 110 forces the first fluid source
152 to drive fluid through the fluid path 105. In some embodi
ments, the first pump 110 includes an electro-magnetically
driven linear actuator (e.g., LINEAR MOTORS LINMOT®
P linear motor, available from LinMot® Inc., Delavan, Wis.)
coupled to the first fluid source 152.
The second pump 115 can include, but is not limited to, at
least one of a syringe pump and some other type of linear or
non-linear actuator. For example, in some embodiments, such
as the embodiment illustrated in FIG. 1, the second pump 115
includes an electro-magnetically driven linear actuator (e.g.,
LINEAR MOTORS LINMOT® P linear motor, available
from LinMot® Inc., Delavan, Wis.) coupled to a second fluid
source 154 (e.g., a syringe), such that the first pump 115
forces the second fluid source 152 to drive fluid through the
fluid path 105. It should be understood that the first and
second fluid sources 152,154 do not need to include syringes,
but rather can include a variety of types of fluid sources
known to those of ordinary skill in the art.
In some embodiments, the one or more flow chambers 145
are defined at least partially by an inner surface 162 of a body
166. As shown in FIG. 1, the body 166 includes a first portion
170 and a second portion 174, which can move relative to one
another to allow a support 150 to be placed inside each flow
chamber 145. The first portion 170 and the second portion
174 can be sealed together and held in a sealed positioned by
one or more closures 176. As shown in FIG. 1, the body 166
includes two legs 180 coupled to the second portion 174 of the
body 166. The legs 180 can be used to hold the second portion
174 in place while a support 150 is positioned within, or
removed from, each flow chamber 145. The closures 176 and
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legs 180 are illustrated by way of example only, but it should
be understood by one of ordinary skill in the art that the body
166 can be sealed and supported in a variety of other ways
without departing from the spirit and scope of the present
invention. Furthermore, the body 166 illustrated in FIGS. 1
and 2 is shown by way of example only. In some embodi
ments, the body 166 only includes one portion that defines the
flow chambers 145. Other bodies 166 and flow chamber struc
tures and shapes can be used without departing from the spirit
and scope of the present invention.
In the embodiment illustrated in FIG. 1, the flow chambers
145 are fluidly coupled in parallel to the first pump 110 and
the second pump 115 via the first connector 120. In some
embodiments, as shown in FIG. 1, each flow chamber 145 is
connected to the fluid path 105 downstream of the first con
nector 120 via a third connector 177 (e.g., a three-way valve).
In some embodiments employing more than one flow cham
ber 145, the flow chambers 145 are fluidly coupled in series to
the first pump 110 and the second pump 115, such that con
ditioned media 159 flows from one flow chamber 145 into
another flow chamber 145, and a collection reservoir 155, if
employed, is fluidly coupled to the last flow chamber 145. In
the embodiment illustrated in FIG. 1, the body 166 includes
four flow chambers 145. Fiowever, it should be understood
that the body 166 can include as few as one flow chamber 145
and as many as structurally feasible or necessary for a par
ticular application. For the sake of clarity and brevity, one
flow chamber 145 will be described herein.
The body 166 can be formed of a variety of materials
including, but not limited to, a polymer, such as acrylic or
polycarbonate, and combinations thereof. Accordingly, the
flow chamber 145 can be formed in the body 166 by a variety
of methods, including, without limitation, at least one of
molding, casting, forging and machining. As illustrated in
FIG. 2, the flow chamber 145 includes an inlet 178 positioned
to allow fluid to enter the flow chamber 145 and an outlet 182
positioned to allow fluid to exit the flow chamber 145. Fiow
ever, in some embodiments, the flow chamber 145 may not
include an outlet 182 and the flow chamber 145 may serve as
the final destination in the fluid path 105.
The first portion 170 of the body 166 includes a first bore
186 defined therein that includes a first opening 188, which is
in fluid communication with the first connector 120, and a
second opening 190, which is in fluid communication with
the inlet 178 ofthe flow chamber 145. The second portion 174
includes a second bore 192 defined therein that includes a first
opening 194, which is fluid communication with the outlet
182 of the flow chamber 145, and a second opening 196,
which is in fluid communication with the collection reservoir
155. Thus, the first opening 188 of the first bore 186 defines an
inlet in the body 166, and the second opening 196 of the
second bore 192 defines an outlet in the body 166.
The first bore 186 and the second bore 192 can have a
variety of dimensions. In some embodiments, the first bore
186 and the second bore 192 are substantially cylindrical and
each have a diameter. In the embodiment illustrated in FIG. 2,
the inlet 178 of the flow chamber 145 has a diameter greater
than that of the first bore 186 and the outlet 182 of the flow
chamber 145 to allow for the support 150 to be positioned and
maintained within the flow chamber 145. For example, in
some embodiments, the diameter of the first bore 186 and the
diameter of the outlet 182 of the flow chamber 145 are each
about 0.125 inches, and the diameter of the inlet 178 of the
flow chamber 145 is about 1 inch to allow the support 150 to
be positioned within the flow chamber 145.
A recess 195 is further defined in the second portion 174 of
the body 166 adjacent the inlet 178 of the flow chamber 145.
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As shown in FIG. 2, the recess 195 is also substantially
cylindrical in shape and has a diameter greater than the diam
eter of the inlet 178 of the flow chamber 145. A seal-forming
device 205 (e.g., an o-ring, such as a #11 VITON® o-ring,
available fromAllorings.com, Inc., Fiampton Falls, N.H.) is
positioned within the recess 195 to fluidly seal the first portion
170 and the second portion 174 of the body 166 along an
interface 210. The seal-forming device 205 includes an aper
ture with a diameter about equal to that of the first bore 186 to
allow fluid to pass through the seal-forming device 205 and
into the flow chamber 145.
In some embodiments, the first opening 188 of the first bore
186 is fluidly coupled to the first connector 120 via a first
tubing 225 and the second opening 196 of the second bore 192
is fluidly coupled to the collection reservoir 155 via a second
tubing 227. In some embodiments, the first tubing 225 is
fluidly coupled to the first opening 188 of the first bore 186,
and the second tubing 227 is fluidly coupled to the outlet 182
of the flow chamber 145 via barbed male-male connectors, as
are well-known to those of ordinary skill in the art. Seal
forming devices 230 (e.g., o-rings) can be used to fluidly seal
the first tubing 225 and the second tubing 227 to the body 166.
In some embodiments, the first tubing 225 and the second
tubing 227 include silicone tubing that is permeable to oxy
gen and carbon dioxide to ensure gas exchange between the
cells 102 in the flow chamber 145 and the environment (e.g.,
silicon tubing, available from Flarvard Apparatus, Flolliston,
Mass.).
In the embodiment illustrated in FIG. 2, the support 150 is
positioned within the flow chamber 145. In some embodi
ments, the support 150 can include, but is not limited to, at
least one of a scaffold, a matrix, a gel, and combinations
thereof. For example, in some embodiments, the support 150
includes a substantially cylindrical, porous calcium phos
phate scaffold (e.g., a 3D Calcium Phosphate Scaffold, avail
able from BD™ Biosciences, Bedford, Mass,).
Cells 102 can be positioned within the flow chamber 145 in
a variety of ways. In some embodiments, the cells 102 are
seeded onto the support 150, and then the seeded support 150
is positioned within the flow chamber 145. In some embodi
ments, the cells 102 are suspended within the support 150
(e.g., within a porous support 150), and then the support 150
containing the cells 102 is positioned within the flow chamber
145. In some embodiments, the cells 102 are suspended
within the flow chamber 145, and the inlet 178 and the outlet
182 are each fitted with a filter to prevent the cells 102 from
flowing out of the flow chamber 145. In some embodiments,
the cells are seeded directly onto the inner surface 162 of the
body 166, such that the inner surface 162 of the body 166
functions as a two-dimensional support positioned within the
flow chamber 145.
The cells 102 can include, but are not limited to, bone cells.
In some embodiments, the cells 102 include osteoblasts and
osteoclasts, and combinations thereof. For example, the cells
102 can include a mouse osteoblastic cell line (e.g., MC3T3
subclone 4 mouse osteoblastic cell line, available from
ATCC, The Global Biosource Center™, Manassas, Va.).
In some embodiments, as shown in FIG. 1, the cell culture
assembly 100 includes four collection reservoirs 155. Fiow
ever, it should be understood that as few as one collection
reservoir 155 and as many as structurally feasible, or neces
sary for a particular application, are possible. The collection
reservoir 155 can be formed by a variety of methods. In some
embodiments, as shown in FIG. 1, the collection reservoir 155
includes a centrifuge tube having a bore defined in its cap 250
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that is sealed by a seal-forming device (e.g., an o-ring), which
allows for facile removal and replacement of the collection
reservoir 155.
In operation, regardless of how the cells 102 are positioned
within the flow chamber 145, fluid is supplied to the first
pump 110 and the second pump 115, and the first pump 110
produces a steady flow of fluid and the second pump 115
produces an oscillatory flow of fluid simultaneously with the
steady flow of fluid through the fluid path 105. The fluids
flowing from the first pump 110 and the second pump 115 are
combined at the first connector 120, and the combined steady
flow and oscillatory flow of fluid flows the inlet 178 of flow
chamber 145 (via the first opening 188 of the first bore 186 in
the first portion 170 of the body 166). The fluid flows through
the flow chamber 145 and, as the fluid flows through the flow
chamber 145, the cells 102 seeded on the support 150 are
subjected to both a steady perfusion of fluid, which transports
nutrients to the cells 102 and carries conditioned media 159
away from the cells 102, and an oscillatory flow of fluid
simultaneously with the steady flow of fluid, which mechani
cally stimulates the cells 102. The fluid may continue to move
through the fluid path 105 and exit the flow chamber 145
through the outlet 182. The fluid can be altered by the cells
102, becoming conditioned media 159, which can be col
lected by the collection reservoir 155.
The first pump 110 and the second pump 115 are capable of
producing a variety of volumetric flow rates, and in addition,
the second pump 115 is capable of producing a variety of flow
rates having a variety of frequencies. For example, in some
embodiments, the second pump 115 produces a volumetric
flow rate of about 40 mL/min., with a frequency of about 2 Flz.
In some embodiments, the frequency of the flow produced by
the second pump 115 is within a generally physiological
frequency range (e.g., from about 0.1 Flz to about 10 Flz). In
some embodiments, the first pump 110 is produces a volu
metric flow rate of about 0.025 mL/min. In some embodi
ments, the first pump 110 is adapted to produce a constant low
flow rate perfusion, relative to that produced by the second
pump 115.
In some embodiments, the second pump 115 is adapted to
produce a constant oscillatory flow of fluid in the fluid path
105. In some embodiments, the second pump 115 is adapted
to produce an intermittent oscillatory flow of fluid. For
example, in some embodiments, the second pump 115 pro
duces an oscillatory flow of fluid at least once daily for a
period of no greater than about 30 minutes.
Cells 102 that may benefit from exposure to a constant
steady flow of fluid from the first pump 110 combined with a
constant oscillatory flow of fluid from the second pump 115
include, but are not limited to, cardiac muscle cells and blood
vessel cells. Cells 102 that may benefit from exposure to a
constant steady flow of fluid from the first pump 110 and an
intermittent oscillatory flow of fluid from the second pump
115 include, but are not limited to, bone cells, ligament cells,
tendon cells, and cartilage cells.
The foregoing description of the present invention has been
presented for purposes of illustration and description. Fur
thermore, the description is not intended to limit the invention
to the form disclosed herein. Consequently, variations and
modifications commensurate with the above teachings, and
the skill or knowledge of the relevant art, are within the scope
of the present invention. The embodiments described herein
are further intended to explain best modes known for practic
ing the invention and to enable others skilled in the art to
utilize the invention in such, or other, embodiments and with
various modifications required by the particular applications
or uses of the present invention. It is intended that the
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appended claims be construed to include alternative embodi
ments to the extent permitted by the prior art.
The following working examples are intended to be illus
trative and not limiting.
EXAMPLE 1
This example describes one embodiment of a cell culture
assembly 100 of the present invention. Four flow chambers
145 were machined out of a polycarbonate body 166, and
each flow chamber 145 housed the cell-seeded supports 150
during experimentation. The polycarbonate body 166
included a first portion 170 and a second portion 174, and the
flow chambers 145 were machined out of the second portion
174. Four first bores 186 were machined out of the first
portion 170, and each first bore 186 was positioned in fluid
communication with the an inlet 178 of each flow chamber
145. Four second bores 192 were machined out of the second
portion 174, and each second bore 192 was coupled to an
outlet 182 of the flow chamber 145. Each flow chamber 145
had a single 1-inch inlet 178 and a single l/s-inch outlet 182.
An l/s-inch barbed connector was threaded into an opening
188 of each first bore 186, and connected to an l/s-inch silicon
tubing. The body 166 included two steel legs 180 that were
screwed into a bottom surface of the second portion 174 of the
polycarbonate body 166. The two steel legs 180 served to
support the body 166 when the supports 150 were being
placed into their respective flow chambers 145. Each flow
chamber 145 was fluidly coupled to a first pump 110, specifi
cally a syringe pump (available from Flarvard Apparatus,
Flollistion, Mass.) coupled to a first fluid source 152 for
producing a steady flow of fluid, and a second pump 115,
specifically an electromagnetic linear actuator (available
from Linmot, Delavan, Wis.) coupled to a second fluid source
154 for producing an oscillatory flow of fluid. Each chamber
145 was also fluidly coupled to a media source 132, and
specifically, to a 140 mL syringe. Each flow chamber 145 was
also fluidly coupled to a collection reservoir 155. The collec
tion reservoirs 155 used to collect conditioned media 159
from the cells 102 included 50 mL centrifuge tubes with an
l/s-inch hole drilled in the cap 250, and an l/s-inch male-male
tubing barb with an #8 VITON® o-ring (available from Allorings.com, Inc., Flampton Falls, N.H.) sealing the tubing to the
cap 250. The first pump 110 provided the constant low flow
rate perfusion, and the second pump 115 generated a laiger
magnitude with an oscillatory flow profile. Thus, the cell
culture assembly 100 provided perfusion with mechanical
stimulation. Flow rates and profiles were monitored with a
detector 125. The detector 125 included a flow probe (avail
able from Transonic Systems Inc., Ithaca, N.Y.). A first con
nector 120, specifically a three-way valve, was used to com
bine the fluid flowing from the first pump 110 and the fluid
flowing from the second pump 115. A second connector 122,
specifically a three-way valve, allowed for the transfer of
fresh media from the media source 132 into the system with
out risk of contamination. Each flow chamber 145 was
coupled to the first connector 120 via a third connector 117,
specifically, a three-way valve. The body 166 was kept in an
incubator at 37° C., 5% carbon dioxide during experimenta
tion.
EXAMPLE 2
This example describes a method that was used to culture
cells 102 using the cell culture assembly set forth in Example
1, compared with cells cultured in static conditions, and cells
cultured with perfusion flow alone. The supports 150 used
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included a 3D cylindrical, porous calcium phosphate scaffold
with a 5 mm diameter and a 3.5 mm height. The cells 102 used
for mechanical stimulation included a mouse osteoblastic cell
line MC3T3 subclone 4. The cells 102 were first cultured in
standard MC3T3 media comprising MEM-a (e.g., GIBCO®
Advanced MEM basal media, available from Invitrogen™,
Carlsbad, Calif.), 10% fetal bovine serum (e.g., BOVINE
GROWTE1 SERUM™ fetal bovine serum, available from
ElyClone, Logan, Utah), and 1% penicillin/streptomycin
(CELLGRO® penicillin/streptomycin, available from Medi
ated!, Inc., Elerndon, Va.). The cells 102 were then statically
seeded on the supports 150 by suspending 100,000 cells 102
in 40 pi of media and then seeding the resulting suspension
onto the supports 150. The seeded supports 150 were then
incubated at 37° C. for 1 hour in a 24-well plate to allow the
cells 102 to adhere to the supports 150. The cell-seeded sup
ports 150 were covered with 2 mL of media and allowed to
incubate for 24 hours prior to being loaded into the flow
chambers 145. Following the incubation period, the supports
150 were positioned in the flow chambers 145, which were
kept in an incubator at 37° C., 5% carbon dioxide. MC3T3
media perfusion was initiated by the first pump 110 at a rate
of 0.025 ml/min. Four hours after perfusion began, the first
mechanical loading bout (i.e., an oscillatory fluid flow) was
initiated by the second pump 115 at a rate of 40mL/min, with
a frequency of 1 Flz for 30 min, to allow exposure of the cells
102 to an intermittent oscillatory flow superimposed with the
steady perfusion from the first pump 110. One bout of oscil
latory fluid flow was performed daily for 2 days. For static
culture conditions, the supports 150 remained in 24-well
plates with 2 mL of MC3T3 media. For the static cultures,
media changes were performed every 24 hours. The incubator
was maintained at 37° C., with 5% C 02 throughout the dura
tion of the experiment. DNA and prostaglandin E2were quan
tified for six supports 150 for each condition (static, perfu
sion, and perfusion with mechanical stimulation) at both 24
and 48 hours for a total of 36 supports 150.
The steady flow of fluid was estimated to expose the cells
102 to a shear stress of about 0.0008 Pa, and the oscillatory
flow of fluid was estimated to expose the cells 102 to a shear
stress of 1.3 Pa once daily for a period of 30 min. at 1 Flz for
the perfusion with mechanical stimulation group. Every 24
hours, conditioned media 159 was collected and analyzed for
prostaglandin E2 (PGE2) using a BIOTRAK™ PGE2 com
petitive enzyme immunoassay (available from Amersham
Biosciences, Piscataway, N.J.).
The supports 150 were removed after 24 or 48 hours and
genomic DNA was isolated using the GenomicPrep kit (avail
able from Amersham Biosciences, Piscataway, N.J.). Cell
membranes were lysed while the DNA remained hydrated,
RNA was degraded using RNase A, and protein was precipi
tated and discarded. DNA was isolated using isopropanol
precipitation and washed with 70% ethanol. After isolation,
total DNA was quantified with a Nanodrop Spectrophotom
eter (available from Nanodrop Technologies, Rockland,
Del.).
Every 24 hours, conditioned media 159 was collected from
the flow chambers 145, and the 24-well plates that contained
the statically cultured supports 150. The conditioned media
was frozen at -20° C. The PGE2 levels were determined using
a BIOTRAK™ PGE2 competitive enzyme immunoassay
(available from Amersham Biosciences, Piscataway, N.J.).
The assay was performed in duplicate using 50 pL samples
from all conditioned media 159 samples. The reaction was
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halted prior to endpoint determination using 1M sulfuric acid
and read at 450 nm using a VERSAmax microplate reader
(available from Molecular Devices Corporation, Sunnyvale,
Calif.). The duplicate optical density values were corrected
for nonspecific binding and averaged, and compared to a
standard curve to determine the amount of PGE2 in each
sample. These values were normalized by the total genomic
DNA in the corresponding support 150. Analysis of variance
for normalized PGE2 levels were followed up by Fisher’s
PLSD test at a significance level of 0.05 using SAS statistical
software.
As shown in FIG. 3, at 24 hours, both perfusion flow alone
and perfusion flow with mechanical stimulation significantly
(p<0.001) increased PGE2 release from the cells 102 seeded
on the supports 150, compared to static controls. The greatest
increase was in the mechanical stimulation group, which had
PGE2 levels significantly larger than the other two groups.
Perfusion flow caused a 2.5-fold increase in PGE2 levels
compared to static culture after 24 hours, and mechanical
loading caused a 4.5-fold increase. Similar trends were seen
at 48 hours; however the difference between the static and
perfusion groups was not significant. With continued refer
ence to FIG. 3, at 48 hours, the mechanical group was sig
nificantly (p<0.034) different from the perfusion and static
groups. Mechanical stimulation produced about 80% more
PGE2 release than perfusion flow after 24 hours, and 77%
more after 48 hours.
What is claimed is:
1. A method for culturing cells, the method comprising:
providing a flow chamber positioned in a fluid path;
providing a porous support positioned within the flow
chamber, the support comprising cells;
transporting fluid in the fluid path at a substantially steady
flow rate to transport fluid past the cells; and
transporting fluid in the fluid path at a substantially oscil
latory flow rate simultaneously with transporting fluid in
the fluid path at a substantially steady flow rate, wherein
the oscillatory transport of fluid occurs intermittently.
2. The method of claim 1, further comprising detecting at
least one of the substantially steady flow rate and the substan
tially oscillatory flow rate in the fluid path.
3. The method of claim 2, further comprising controlling at
least one of the substantially steady flow rate and the substan
tially oscillatory flow rate responsive to detecting at least one
of the substantially steady flow rate and the substantially
oscillatory flow rate in the fluid path.
4. The method of claim 1, further comprising delivering a
biomolecule to the fluid path, the biomolecule adapted to
produce a desired effect in the cells.
5. The method of claim 1, wherein transporting fluid in the
fluid path at a substantially steady flow rate includes trans
porting nutrients to the cells and transporting conditioned
media away from the cells.
6. The method of claim 1, wherein transporting fluid in the
fluid path at a substantially oscillatory flow rate includes
mechanically stimulating the cells.
7. The method of claim 1, wherein transporting fluid in the
fluid path at a substantially steady flow rate includes trans
porting fluid at a volumetric flow rate ranging from about 0.01
mL/min to about 3 mL/mm.
8. The method of claim 1, wherein the intermittent oscil
latory fluid transport occurs thirty minutes per day.

